{"transactions":[{"id":853109,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-03-09T23:42:53.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":3048,"price":30.19,"value":92019.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amendment corrects the number of shares and price sold to cover taxes on the initial Form 4 filed on March 4, 2026, as well as the resulting total number of shares beneficially owned following all transactions reported in the initial Form 4."}],"balance_after":13361,"source":{"system":"sec-edgar","filing":"0001193125-26-099014","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526099014/ownership.xml","form_type":"4/A","original_submission_date":"2026-03-04"}},{"id":860711,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-04T23:58:34.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":9409,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":28227,"derivative":{"underlying":"Common Stock","underlying_shares":9409},"source":{"system":"sec-edgar","filing":"0001193125-26-092040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092040/ownership.xml","form_type":"4"}},{"id":860710,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-04T23:58:34.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":35300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":35300,"derivative":{"underlying":"Common Stock","underlying_shares":35300},"source":{"system":"sec-edgar","filing":"0001193125-26-092040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092040/ownership.xml","form_type":"4"}},{"id":860709,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-04T23:58:34.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":176550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.  The date of the grant is March 2, 2026."}],"balance_after":176550,"derivative":{"exercise_price":30.25,"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":176550},"source":{"system":"sec-edgar","filing":"0001193125-26-092040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092040/ownership.xml","form_type":"4"}},{"id":860708,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-03-04T23:58:34.000Z","date":"2026-03-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":3138,"price":29.32,"value":92006.16,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the \"ESPP\") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c)."}],"balance_after":13271,"source":{"system":"sec-edgar","filing":"0001193125-26-092040","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092040/ownership.xml","form_type":"4"}},{"id":860707,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-03-04T23:58:34.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":9409,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the \"ESPP\") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c)."}],"balance_after":16409,"source":{"system":"sec-edgar","filing":"0001193125-26-092040","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526092040/ownership.xml","form_type":"4"}},{"id":1226472,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-05T02:13:31.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":37636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":37636,"derivative":{"underlying":"Common Stock","underlying_shares":37636},"source":{"system":"sec-edgar","filing":"0000950170-25-032887","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017025032887/ownership.xml","form_type":"4"}},{"id":1226471,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-05T02:13:31.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":225814,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date.  The date of the grant is March 3, 2025."}],"balance_after":225814,"derivative":{"exercise_price":14.41,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":225814},"source":{"system":"sec-edgar","filing":"0000950170-25-032887","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017025032887/ownership.xml","form_type":"4"}},{"id":1397774,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2024-09-30T23:12:50.000Z","date":"2024-09-27","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":23.41,"value":117050.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the \"ESPP\") on September 19, 2024 in transactions that were exempt under Rule 16b-3(c)."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0000950170-24-110485","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017024110485/ownership.xml","form_type":"4"}},{"id":1752357,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-01T20:35:05.000Z","date":"2023-10-30","kind":"grant","planned":false,"acquired":true,"shares":474400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% on October 30, 2024 and then in equal monthly installments over the following 36 months, subject to the Reporting Person's continued service to Issuer through each vesting date."}],"balance_after":474400,"derivative":{"exercise_price":13.02,"expiration_date":"2023-10-30","underlying":"Common Stock","underlying_shares":474400},"source":{"system":"sec-edgar","filing":"0000950170-23-057520","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000095017023057520/ownership.xml","form_type":"4"}},{"id":2098341,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-12-02T21:26:38.000Z","date":"2022-11-30","kind":"grant","acquired":true,"shares":3000,"price":0.94,"value":2820.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the \"ESPP\") for the ESPP purchase period of June 1, 2022 through November 30, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 1, 2022."}],"balance_after":19897,"source":{"system":"sec-edgar","filing":"0000899243-22-037435","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924322037435/doc4.xml","form_type":"4"}},{"id":2199088,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-02T01:14:50.000Z","date":"2022-08-01","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is August 1, 2022."}],"balance_after":75000,"derivative":{"exercise_price":1.57,"expiration_date":"2032-07-31","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-22-027273","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924322027273/doc4.xml","form_type":"4"}},{"id":2242404,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2022-06-06T20:05:16.000Z","date":"2022-05-31","kind":"grant","acquired":true,"shares":3000,"price":0.99,"value":2970.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Magenta Therapeutics, Inc. 2019 Employee Stock Purchase Plan (the \"ESPP\") for the ESPP purchase period of December 1, 2021 through May 31, 2022. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 31, 2022."}],"balance_after":16897,"source":{"system":"sec-edgar","filing":"0000899243-22-021182","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924322021182/doc4.xml","form_type":"4"}},{"id":2263745,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-19T20:18:57.000Z","date":"2022-05-17","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in three equal installments, each installment vesting every six months, over the 18 months following the vesting commencement date. The vesting commencement date is May 15, 2022."}],"balance_after":50000,"derivative":{"exercise_price":1.18,"expiration_date":"2032-05-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-22-018801","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924322018801/doc4.xml","form_type":"4"}},{"id":2388583,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-17T22:15:40.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in 16 equal quarterly installments beginning on the first quarter following the vesting commencement date. The vesting commencement date is February 1, 2022."}],"balance_after":75000,"derivative":{"exercise_price":3.19,"expiration_date":"2032-02-14","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-22-006813","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924322006813/doc4.xml","form_type":"4"}},{"id":2564074,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-09-20T21:00:26.000Z","date":"2021-09-16","kind":"sale","acquired":false,"shares":6103,"price":6.73,"value":41073.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction represents shares sold solely to pay taxes due upon the vesting of restricted stock units, as disclosed by the reporting person on the Form 4 filed on September 16, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.60 to $6.87, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":13897,"source":{"system":"sec-edgar","filing":"0000899243-21-036598","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924321036598/doc4.xml","form_type":"4"}},{"id":2567771,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-09-16T23:39:01.000Z","date":"2021-09-14","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 14, 2021, the reporting person was granted 40,000 restricted stock units. The restricted stock units vest in two equal installments subject to the achievement of certain performance milestones related to the issuer's business plans. The first performance milestone was achieved, resulting in vesting of 20,000 restricted stock units and the corresponding issuance of 20,000 shares of issuer common stock."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0000899243-21-036332","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924321036332/doc4.xml","form_type":"4"}},{"id":2668361,"issuer":{"id":1813,"kind":"organization","name":"Dianthus Therapeutics, Inc. /DE/","symbol":"DNTH"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-15T20:33:15.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exerciseable over four years, with 25% of this option vesting on June 14, 2022, and the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":200000,"derivative":{"exercise_price":11.37,"expiration_date":"2031-06-13","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-21-023865","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1690585/000089924321023865/doc4.xml","form_type":"4"}},{"id":2774948,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Restricted Share Units","published_at":"2021-03-23T21:32:56.000Z","date":"2021-03-20","kind":"grant","acquired":true,"shares":4287,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The performance criteria for these RSUs were met.  The RSUs will vest in a single installment on March 20, 2023, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The performance criteria for these RSUs were met.  The RSUs will vest in a single installment on March 20, 2023, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs."}],"balance_after":4287,"derivative":{"underlying":"Class A Common Shares","underlying_shares":4287},"source":{"system":"sec-edgar","filing":"0001179110-21-003728","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911021003728/edgar.xml","form_type":"4"}},{"id":2774947,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Restricted Share Units","published_at":"2021-03-23T21:32:56.000Z","date":"2021-03-20","kind":"grant","acquired":true,"shares":5855,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The performance criteria for these RSUs were met.  The RSUs will vest in a single installment on March 20, 2022, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The performance criteria for these RSUs were met.  The RSUs will vest in a single installment on March 20, 2022, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs."}],"balance_after":5855,"derivative":{"underlying":"Class A Common Shares","underlying_shares":5855},"source":{"system":"sec-edgar","filing":"0001179110-21-003728","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911021003728/edgar.xml","form_type":"4"}},{"id":2779440,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Restricted Share Units","published_at":"2021-03-18T23:07:47.000Z","date":"2021-03-16","kind":"grant","acquired":true,"shares":8769,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021."}],"balance_after":8769,"derivative":{"underlying":"Class A Common Shares","underlying_shares":8769},"source":{"system":"sec-edgar","filing":"0001179110-21-003615","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911021003615/edgar.xml","form_type":"4"}},{"id":2779439,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Share Option","published_at":"2021-03-18T23:07:47.000Z","date":"2021-03-16","kind":"grant","acquired":true,"shares":52611,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is March 16, 2021."}],"balance_after":52611,"derivative":{"exercise_price":22.89,"expiration_date":"2031-03-15","underlying":"Class A Common Shares","underlying_shares":52611},"source":{"system":"sec-edgar","filing":"0001179110-21-003615","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911021003615/edgar.xml","form_type":"4"}},{"id":2876712,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Class B Common Shares","published_at":"2021-02-05T23:55:16.000Z","date":"2021-02-03","kind":"exercise","acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Class B Common Share is convertible at any time at the election of the holder into one Class A Common Share or one Class B1 Common Share and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Class B Common Share is convertible at any time at the election of the holder into one Class A Common Share or one Class B1 Common Share and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Class B Common Share is convertible at any time at the election of the holder into one Class A Common Share or one Class B1 Common Share and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party."}],"balance_after":114157,"derivative":{"underlying":"Class A Common Shares","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001179110-21-001370","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911021001370/edgar.xml","form_type":"4"}},{"id":2876711,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Class A Common Shares","published_at":"2021-02-05T23:55:16.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":2477,"price":22.09,"value":54716.93,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on June 19, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $22.05 to $22.18. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price."}],"balance_after":297523,"source":{"system":"sec-edgar","filing":"0001179110-21-001370","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911021001370/edgar.xml","form_type":"4"}},{"id":2876710,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Class A Common Shares","published_at":"2021-02-05T23:55:16.000Z","date":"2021-02-03","kind":"exercise","acquired":true,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Class B Common Share is convertible at any time at the election of the holder into one Class A Common Share or one Class B1 Common Share and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party."}],"balance_after":300000,"source":{"system":"sec-edgar","filing":"0001179110-21-001370","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911021001370/edgar.xml","form_type":"4"}},{"id":3032403,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Share Option","published_at":"2020-09-14T21:14:34.000Z","date":"2020-09-10","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 10, 2020."}],"balance_after":75000,"derivative":{"exercise_price":15.5,"expiration_date":"2030-09-09","underlying":"Class A Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001179110-20-009722","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911020009722/edgar.xml","form_type":"4"}},{"id":3092288,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Class A Common Shares","published_at":"2020-07-02T20:13:40.000Z","date":"2020-07-01","kind":"sale","acquired":false,"shares":2855,"price":25.84,"value":73773.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1plan executed by the reporting person on December 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $25.78 to $25.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price"}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-080552","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465920080552/a4.xml","form_type":"4"}},{"id":3092287,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Class A Common Shares","published_at":"2020-07-02T20:13:40.000Z","date":"2020-07-01","kind":"sale","acquired":false,"shares":26734,"price":25.32,"value":676904.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1plan executed by the reporting person on December 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $24.77 to $25.74. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price"}],"balance_after":2855,"source":{"system":"sec-edgar","filing":"0001104659-20-080552","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465920080552/a4.xml","form_type":"4"}},{"id":3112050,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Share Option","published_at":"2020-06-12T21:50:14.000Z","date":"2020-06-10","kind":"exercise","acquired":false,"shares":13752,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on December 24, 2019."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Share Option granted the reporting person an option to purchase 125,941 Shares. 25% of such Shares vested and became exercisable on August 1, 2016, and 1/36 of the remainder of the Shares vested and became exercisable monthly thereafter."}],"balance_after":112189,"derivative":{"exercise_price":1.59,"expiration_date":"2025-12-15","underlying":"Class A Common Shares","underlying_shares":13752},"source":{"system":"sec-edgar","filing":"0001179110-20-007295","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911020007295/edgar.xml","form_type":"4"}},{"id":3112049,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Class A Common Shares","published_at":"2020-06-12T21:50:14.000Z","date":"2020-06-10","kind":"sale","acquired":false,"shares":13752,"price":25.07,"value":344762.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on December 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $25.00 to $25.20. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price."}],"balance_after":29589,"source":{"system":"sec-edgar","filing":"0001179110-20-007295","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911020007295/edgar.xml","form_type":"4"}},{"id":3112048,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Class A Common Shares","published_at":"2020-06-12T21:50:14.000Z","date":"2020-06-10","kind":"exercise","acquired":true,"shares":13752,"price":1.59,"value":21865.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this From 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on December 24, 2019."}],"balance_after":43341,"source":{"system":"sec-edgar","filing":"0001179110-20-007295","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911020007295/edgar.xml","form_type":"4"}},{"id":3171790,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Class A Common Shares","published_at":"2020-04-22T21:39:10.000Z","date":"2020-04-21","kind":"sale","acquired":false,"shares":955,"price":20.44,"value":19520.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of Class A Common Shares reported in this From 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on December 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $20.12 to $20.60. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price."}],"balance_after":29589,"source":{"system":"sec-edgar","filing":"0001179110-20-005046","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911020005046/edgar.xml","form_type":"4"}},{"id":3171789,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Class A Common Shares","published_at":"2020-04-22T21:39:10.000Z","date":"2020-04-21","kind":"sale","acquired":false,"shares":1563,"price":19.56,"value":30572.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of Class A Common Shares reported in this From 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on December 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.07 to $20.05. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price."}],"balance_after":30544,"source":{"system":"sec-edgar","filing":"0001179110-20-005046","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911020005046/edgar.xml","form_type":"4"}},{"id":3171788,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Class A Common Shares","published_at":"2020-04-22T21:39:10.000Z","date":"2020-04-20","kind":"sale","acquired":false,"shares":47423,"price":19.06,"value":903882.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of Class A Common Shares reported in this From 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on December 24, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.00 to $19.17. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price."}],"balance_after":32107,"source":{"system":"sec-edgar","filing":"0001179110-20-005046","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911020005046/edgar.xml","form_type":"4"}},{"id":3205630,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Share Option","published_at":"2020-03-17T21:23:12.000Z","date":"2020-03-13","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 13, 2020."}],"balance_after":75000,"derivative":{"exercise_price":15.52,"expiration_date":"2030-03-12","underlying":"Class A Common Shares","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001179110-20-003835","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911020003835/edgar.xml","form_type":"4"}},{"id":3263685,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Class A Common Shares","published_at":"2020-02-19T22:24:57.000Z","date":"2020-02-14","kind":"sale","acquired":false,"shares":59,"price":18.58,"value":1096.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of Class A Common Shares reported in this From 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on December 24, 2019."}],"balance_after":79530,"source":{"system":"sec-edgar","filing":"0001179110-20-001872","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911020001872/edgar.xml","form_type":"4"}},{"id":3409920,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Share Option","published_at":"2019-09-19T20:18:07.000Z","date":"2019-09-17","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 17, 2019."}],"balance_after":45000,"derivative":{"exercise_price":8.83,"expiration_date":"2029-09-16","underlying":"Class A Common Shares","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001179110-19-010489","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000117911019010489/edgar.xml","form_type":"4"}},{"id":3608616,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Share Option","published_at":"2019-03-06T23:28:19.000Z","date":"2019-03-04","kind":"grant","acquired":true,"shares":42000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter.  The vesting commencement date is March 4, 2019."}],"balance_after":42000,"derivative":{"exercise_price":17.92,"expiration_date":"2029-03-03","underlying":"Class A Common Shares","underlying_shares":42000},"source":{"system":"sec-edgar","filing":"0001104659-19-013173","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465919013173/a4.xml","form_type":"4"}},{"id":3809141,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Legal Officer"}}],"security":"Share Option","published_at":"2018-09-24T12:57:56.000Z","date":"2018-09-20","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in equal monthly installments over a three-year period thereafter.  The vesting commencement date is September 20, 2018."}],"balance_after":45000,"derivative":{"exercise_price":30.93,"expiration_date":"2028-09-19","underlying":"Class A Common Shares","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001104659-18-058107","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465918058107/a4.xml","form_type":"4"}},{"id":3915660,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Class B Common Shares","published_at":"2018-05-29T23:20:09.000Z","date":"2018-05-29","kind":"exercise","acquired":true,"shares":48172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Class B Common Shares is convertible at any time at the election of the holder into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Class B Common Shares is convertible at any time at the election of the holder into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Class B Common Shares is convertible at any time at the election of the holder into one share of Class A Common Shares or one share of Class B1 Common Shares and will automatically convert into Class A Common Shares upon transfer to an unaffiliated party."}],"balance_after":414157,"derivative":{"underlying":"Class A Common Shares","underlying_shares":48172},"source":{"system":"sec-edgar","filing":"0001104659-18-036487","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465918036487/a4.xml","form_type":"4"}},{"id":3915659,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Series C Preferred Shares","published_at":"2018-05-29T23:20:09.000Z","date":"2018-05-29","kind":"exercise","acquired":false,"shares":6392,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis."}],"balance_after":0,"derivative":{"underlying":"Class A Common Shares","underlying_shares":6392},"source":{"system":"sec-edgar","filing":"0001104659-18-036487","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465918036487/a4.xml","form_type":"4"}},{"id":3915658,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Series A Preferred Shares","published_at":"2018-05-29T23:20:09.000Z","date":"2018-05-29","kind":"exercise","acquired":false,"shares":48172,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class B Common Shares on a one-for-one basis."}],"balance_after":0,"derivative":{"underlying":"Class B Common Shares","underlying_shares":48172},"source":{"system":"sec-edgar","filing":"0001104659-18-036487","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465918036487/a4.xml","form_type":"4"}},{"id":3915657,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Series C Preferred Shares","published_at":"2018-05-29T23:20:09.000Z","date":"2018-02-09","kind":"purchase","acquired":true,"shares":6392,"price":15.6438,"value":99995.1696,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis."},{"field":"shares","element":"transactionShares","label":"F2","text":"Reflects the 1-for-2.73235 share consolidation effected May 11, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the 1-for-2.73235 share consolidation effected May 11, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, the preferred shares automatically converted into the Issuer's Class A Common Shares on a one-for-one basis."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Reflects the 1-for-2.73235 share consolidation effected May 11, 2018."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the 1-for-2.73235 share consolidation effected May 11, 2018."}],"balance_after":6392,"derivative":{"underlying":"Class A Common Shares","underlying_shares":6392},"source":{"system":"sec-edgar","filing":"0001104659-18-036487","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465918036487/a4.xml","form_type":"4"}},{"id":3915656,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":61972,"kind":"person","name":"Beetham Thomas W.","position":1,"cik":"0001741382","reported_name":"Beetham Thomas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Class A Common Shares","published_at":"2018-05-29T23:20:09.000Z","date":"2018-05-29","kind":"exercise","acquired":true,"shares":6392,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":79589,"source":{"system":"sec-edgar","filing":"0001104659-18-036487","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465918036487/a4.xml","form_type":"4"}}]}